How does Mounjaro stack up for cardiovascular protection? The SURPASS CVOT results

In choosing the best GLP1-based medication for our patients with type 2 diabetes at high risk of cardiovascular disease, guidelines recommend choosing one that has proven reduction in risk of CV events in cardiovascular outcome trials (CVOTs). High level results just released on Mounjaro's SURPASS CVOT study tell us how mounjaro stacks up. Read on to find out!Learn more: https://drsue.ca/2025/08/how-does-mounjaro-stack-up-for-cardiovascular-protection-the-surpass-cvot-results/Any medical discussion on this podcast is intended to be of a general nature only, and is intended for a Canadian audience. This podcast is not designed to give specific medical advice to patients, nor to their health care providers. If you have a medical problem you should consult your own physician for advice specific to your own situation. Postings on this podcast represent the personal opinions of Dr. Sue Pedersen. They are not representative of, nor endorsed by, Alberta Health Services. This podcast is intended for the Canadian general public as well as Canadian allied health professionals.

There are no comments yet.

Please log in to write the first comment.